Effectiveness of Nirsevimab in Infants Against Respiratory Syncytial Virus and Related Events

• 2024

  Log in to bookmark this resource.

  Log in
• Amber Hsiao; John Hansen; Julius Timbol; Bruce Fireman; Ousseny Zerbo; Karine Mari
DOI: https://doi.org/10.1016/j.anai.2024.10.008

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article discusses a study on nirsevimab, a treatment for infants to prevent respiratory syncytial virus (RSV), which is common in lower respiratory tract diseases. The study included 31,900 infants and found that those treated with nirsevimab had an 87% reduced risk of RSV-related illness compared to untreated infants. Treated infants also had fewer medical visits and were less likely to be hospitalized. The research shows that nirsevimab is effective in reducing RSV risks across various healthcare settings for healthy-term infants born after April 2023.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Hospitalization; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Antibodies, Monoclonal, Humanized

Institutions: Kaiser Permanente

---

More like this

Uptake of Maternal RSV Vaccination and Infant Nirsevimab Among Infants Born October 2023 to March 2024 2025 · Kaiser Permanente Effectiveness of Nirsevimab in Infants Against Respiratory Syncytial Virus and Related Events 2024 · Kaiser Permanente Healthcare Providers' and Pregnant People's Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus 2024 · Oracle Life Sciences, Pfizer Inc.

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---